Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the future, as standard screening measure. Adult...
Age: 18 - 89 years
Gender: All
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
Black and Latina women experience disparities in supportive and palliative care access and
outcomes. The goal of the proposed pilot study is to evaluate the feasibility and
acceptability of a community navigator delivered supportive care intervention for
historica...
Age: 18 years - 66+
Gender: Female
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
Age: 18 years - 66+
Gender: Male
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level of
care to the right patients at the right time. It represents an adaption of the Mount Sinai
PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. ...
Age: 18 years - 66+
Gender: All
Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening
The purpose of this research study is to evaluate the efficacy of a digital navigation tool,
called the eNav to improve colorectal cancer screening uptake among patients treated at
federally qualified health centers (FQHC)s. The digital navigation tool includes a we...
Age: 45 - 75 years
Gender: All
Mobile Ostomates Resources for Patients and Caregivers
The scope of this research is to examine the acceptability and feasibility of a refined web-based intervention ("STOMA Care" app) by conducting a randomized pilot consisting of bladder and colorectal cancer patients scheduled for ostomy surgery at Mount Sinai Health Sys...
Age: 21 years - 66+
Gender: All
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to...
Age: 18 years - 66+
Gender: All
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and
paclitaxel combination therapy in patients with relapsed or refractory extensive stage small
cell lung cancer.
Age: 18 years - 66+
Gender: All
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
This phase II/III trial examines whether patients who have undergone surgical removal of
bladder, but require an additional treatment called immunotherapy to help prevent their
bladder cancer from coming back, can be identified by a blood test. Many types of tumors ...
Age: 18 years - 66+
Gender: All
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the
bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study
will try to find out if the drugs disitamab vedotin with pembrolizumab works bet...
Age: 18 years - 66+
Gender: All
Ritlecitinib in CTCL
The purpose of this research study is to evaluate the effectiveness and safety of
Ritlecitinib in skin and blood in persons with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a
rare type of cancer that starts in the white blood cells and eventually can result in rashes
...
Age: 18 years - 66+
Gender: All
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition
to standard of care chemotherapy versus standard of care chemotherapy alone in treating
patients with colorectal cancer that has spread to the liver (liver metastases) and ...
Age: 18 years - 66+
Gender: All
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel,
oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for
controlling the growth and/or spreading of the disease in patients with gastric or
gastroe...
Age: 18 years - 66+
Gender: All
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in
cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The
Expansion Phase will begin in parallel one dose level lower than the highest dose deemed s...
Age: 18 years - 66+
Gender: All
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunother...
Age: 18 years - 66+
Gender: All
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
This study is researching an investigational drug called fianlimab (also called REGN3767)
with two other medications called cemiplimab and chemotherapy, individually called a "study
drug" or collectively called "study drugs". 'Investigational' means that the study d...
Age: 18 years - 66+
Gender: All
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the
combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the
treatment of pre- and postmenopausal women and men who have previously received ribo...
Age: 18 years - 66+
Gender: All
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramuciruma...
Age: 18 years - 66+
Gender: All
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
The goal of this clinical trial is to test if the addition of botensilimab to standard
chemotherapy improves the efficacy compared to just chemotherapy alone in participants with
metastatic pancreatic cancer. One group of participants will only receive chemotherapy ...
Age: 18 years - 66+
Gender: All
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the
urinary system and other solid tumor cancers that have a change in a particular gene (known...
Age: 18 years - 66+
Gender: All